https://scholars.lib.ntu.edu.tw/handle/123456789/494942
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | BIN-CHI LIAO | en_US |
dc.contributor.author | Chia-Chi Lin | en_US |
dc.contributor.author | JIH-HSIANG LEE | en_US |
dc.contributor.author | CHIH-HSIN YANG | en_US |
dc.creator | Liao B.-C;Lin C.-C;Lee J.-H;Chih-Hsin Yang | - |
dc.date.accessioned | 2020-05-26T09:26:36Z | - |
dc.date.available | 2020-05-26T09:26:36Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019622634&doi=10.1016%2fj.lungcan.2017.05.009&partnerID=40&md5=8d5c98933633d7627f691b1e50c92552 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/494942 | - |
dc.description.abstract | The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, and the second-generation EGFR-TKI, afatinib, have all been approved as standard first-line treatments for advanced EGFR-mutant non-small cell lung cancer (NSCLC) based on superior progression-free survival results compared to platinum doublet chemotherapy regimens. Acquired resistance to an EGFR-TKI inevitably develops after a period of effective drug treatment. After tumor progression, many combination therapy regimens that include an EGFR-TKI, or EGFR-TKI monotherapy, have been tested in prospective trials with the aim of extending survival. Third-generation EGFR-TKIs such as osimertinib have been developed with the aim of overcoming the effects of EGFR T790M resistance mutation, which occurs in half of the patients with disease progression on EGFR-TKI therapy. Osimertinib has become the standard treatment in patients for whom tumor re-biopsy reveals an acquired EGFR T790M mutation following EGFR-TKI therapy. Other third-generation EGFR-TKIs, such as olmutinib, EGF816, and ASP8273, are still in the trial phase. ? 2017 Elsevier B.V. | - |
dc.publisher | Elsevier Ireland Ltd | - |
dc.relation.ispartof | Lung Cancer | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | afatinib; cetuximab; cytotoxic agent; epidermal growth factor receptor; erlotinib; gefitinib; naquotinib; nazartinib; olmutinib; osimertinib; protein tyrosine kinase inhibitor; rociletinib; antineoplastic agent; epidermal growth factor receptor; protein kinase inhibitor; scatter factor receptor; cancer chemotherapy; cancer combination chemotherapy; cancer survival; cancer therapy; disease course; gene amplification; gene mutation; human; information retrieval; liquid biopsy; lung biopsy; Medline; non small cell lung cancer; priority journal; Review; tumor biopsy; algorithm; disease exacerbation; disease management; drug development; genetics; lung tumor; molecularly targeted therapy; mutation; non small cell lung cancer; pathology; treatment outcome; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Management; Disease Progression; Drug Discovery; Gene Amplification; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Receptor, Epidermal Growth Factor; Treatment Outcome | - |
dc.title | Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy | en_US |
dc.type | Review | en |
dc.identifier.doi | 10.1016/j.lungcan.2017.05.009 | - |
dc.identifier.pmid | 28676222 | - |
dc.identifier.scopus | 2-s2.0-85019622634 | - |
dc.relation.pages | 7��13�� | - |
dc.relation.journalvolume | 110 | - |
item.openairetype | Review | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.orcid | 0000-0002-7092-0764 | - |
crisitem.author.orcid | 0000-0002-8716-1602 | - |
crisitem.author.orcid | 0000-0002-5586-5138 | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。